Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Acquisitions (2021 - 2022)

Dexcom (DXCM) has disclosed Acquisitions for 2 consecutive years, with $700000.0 as the latest value for Q3 2022.

  • Quarterly Acquisitions fell 97.78% to $700000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $700000.0 through Jun 2023, down 97.9% year-over-year, with the annual reading at $3.9 million for FY2022, 87.09% down from the prior year.
  • Acquisitions for Q3 2022 was $700000.0 at Dexcom, down from $3.2 million in the prior quarter.
  • The five-year high for Acquisitions was $31.6 million in Q3 2021, with the low at -$1.4 million in Q4 2021.